Global Osteosarcoma Market Research Report—Forecast till 2025

Global Osteosarcoma Market: Information by Type (Intramedullary Osteosarcoma, Juxtacortical Osteosarcoma, Extraskeletal Osteosarcoma), Diagnosis & Treatment (Treatment and Diagnosis), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations), by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025

Market Analysis
Osteosarcoma Market is expected to register a CAGR of 6.09% to reach USD 791.08 Million by the year 2025. Osteosarcoma is a common type of bone cancer which is developed in cells which are responsible for formation of bones. In very rare conditions osteosarcoma happens in soft tissue outside the bones. Usually, it mostly occurs in teenagers, young adults, and older adult population. The global osteosarcoma market is predominantly driven by a high incidence of osteosarcoma, increasing expenditure on oncology medicine and research, and growing demand for new treatments. Nevertheless, the high cost of treatment and side-effects of chemotherapy impede the growth of the market. The Global Osteosarcoma Market is taking shape due to a higher incidence of osteosarcoma. For example, the prevalence of primary bone cancer is growing across the world. Under national Institutes of Health (NIH), estimation of around 3,450 new cases of primary bone cancer was registered in 2018 in the US. A high number of incidences of osteosarcoma would support the growth of the market. As per the American Cancer Society, around 800 to 900 new cases of osteosarcoma are diagnosed in the US each year. The incidence of osteosarcoma is found to be high in adolescents and the geriatric population. Similarly, according to an article published in the North American Association of Central Cancer Registries, about 3,809 incident cases of osteosarcoma were identified in patients aged 40 years or older in the year 2018. Additionally, the National Cancer Institutes Surveillance, Epidemiology, and End Results Program estimated the incident rate of 4.4 cases per 1 million people below the age of 24 years in the US each year. The cumulative prevalence of osteosarcoma along with the increasing geriatric population are driving the global osteosarcoma market.

Market Segmentation
The Global Osteosarcoma Market has been segmented into type, diagnosis & treatment, end user, and region. Based on type the Global Osteosarcoma Market has been segmented into intramedullary osteosarcoma, juxtacortical osteosarcoma, and extra skeletal osteosarcoma. Intramedullary osteosarcoma has been estimated to account for the largest market share of 80.3% during the forecast period. Intramedullary osteosarcoma is the most common type of osteosarcoma, which represents approximately 75% of all reported osteosarcoma cases recorded globally. Typically, intramedullary osteosarcoma occurs in children and adults. This type of osteosarcoma is bimodal and primarily peaks during adolescence, and the second peak occurs in adulthood. The distal femur and proximal tibia are two primary sites impacted by intramedullary osteosarcoma. Based on diagnosis & treatment, the global osteosarcoma market has been divided into the treatment and diagnosis. The treatment segment is further divided into chemotherapy, surgery, radiation therapy, and others. The chemotherapy segment includes cisplatin, doxorubicin, epirubicin, and others. The surgery segment contains a limb-sparing surgery and amputation. The diagnosis segment is even more segmented into imaging, biopsies, and blood tests. The imaging segment comprises computerized tomography (CT), magnetic resonance imaging (MRI), X-Ray, positron emission tomography (PET) and others. The biopsies segment includes needle biopsy and surgical biopsy. The blood tests segment includes alkaline phosphatase profiling, lactate dehydrogenase profiling, and others. Based on end-user, the global osteosarcoma market has been divided into hospitals & clinics, diagnostic centres, and academic & research organizations. Its hold biggest market share could be attributed to an increase in the number of patients who have cancer, coupled with a rise in a number of hospitals, and quality care, as well as the availability of skilled and qualified professionals.

Regional Analysis
The Global Osteosarcoma Market is broadly segmented based on region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas represent a market share of 40.02% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest global osteosarcoma market in the year 2018. The Europe region is even more segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries, has been divided into the Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region was classified as China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. It holds the third-largest position in the osteosarcoma market. The market in the Middle East & Africa is likely to show minimum growth by factors such as limited access to and higher availability of treatment facilities. However, the high prevalence of bone cancer population will support growth of the market in the region during the forecast period.

Major Players
Academic research institutes, Pharmaceutical companies, Biotechnology companies and Market research & consulting firms are some of the projected onlookers for the Global Osteosarcoma Market. Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter, Novartis AG, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Mylan N.V., and ADVAXIS, INC. are some of the major players in the Global Osteosarcoma Market.


 


1 EXECUTIVE SUMMARY
1.1 OVERVIEW 18

1.2 MARKET SYNOPSIS 18

1.3 KEY CONTRIBUTING FACTORS 19

2 MARKET INTRODUCTION
2.1 DEFINITION 20

2.2 SCOPE OF THE STUDY 20

2.3 RESEARCH OBJECTIVE 20

2.4 MARKET STRUCTURE 21

3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 22

3.2 PRIMARY RESEARCH 24

3.3 SECONDARY RESEARCH 25

3.4 MARKET SIZE ESTIMATION 25

3.5 FORECAST MODEL 27

3.6 LIST OF ASSUMPTIONS 28

4 MARKET DYNAMICS
4.1 OVERVIEW 29

4.2 DRIVERS 30

4.2.1 HIGH INCIDENCE OF OSTEOSARCOMA 30

4.2.2 RISING EXPENDITURE ON ONCOLOGY MEDICINE AND RESEARCH 30

4.2.3 RISING DEMAND FOR NEW TREATMENTS 30

4.3 RESTRAINTS 31

4.3.1 HIGH COST OF TREATMENT 31

4.3.2 SIDE-EFFECTS OF CHEMOTHERAPY 31

4.4 OPPORTUNITIES 32

4.4.1 ENTERING DEVELOPING ECONOMIES 32

4.5 MACROECONOMIC INDICATORS 33

5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 34

5.1.1 BARGAINING POWER OF SUPPLIERS 35

5.1.2 BARGAINING POWER OF BUYERS 35

5.1.3 THREAT OF NEW ENTRANTS 35

5.1.4 THREAT OF SUBSTITUTES 35

5.1.5 INTENSITY OF RIVALRY 35

5.2 VALUE CHAIN ANALYSIS 36

5.2.1 R&D AND DESIGNING 37

5.2.2 MANUFACTURING 37

5.2.3 DISTRIBUTION 37

5.2.4 MARKETING & SALES 37

5.2.5 POST-SALES MONITORING 37

5.3 EPIDEMIOLOGY DATA 38

5.4 CLINICAL TRIALS ANALYSIS 39

5.5 PIPELINE ANALYSIS 41

5.5.1 PEMETREXED 41

5.5.2 INHALED LIPID CISPLATIN 41

6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE
6.1 OVERVIEW 42

6.2 INTRAMEDULLARY OSTEOSARCOMA 43

6.3 JUXTACORTICAL OSTEOSARCOMA 44

6.4 EXTRASKELETAL OSTEOSARCOMA 44

7 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW 45

7.2 TREATMENT 46

7.2.1 CHEMOTHERAPY 47

7.2.2 SURGERY 47

7.2.3 RADIATION THERAPY 47

7.3 DIAGNOSIS 48

7.3.1 IMAGING 48

7.3.2 BIOPSIES 49

7.3.3 BLOOD TESTS 50

8 GLOBAL OSTEOSARCOMA MARKET, BY END USER
8.1 OVERVIEW 51

8.2 HOSPITALS & CLINICS 52

8.3 DIAGNOSTIC CENTERS 52

8.4 ACADEMIC & RESEARCH ORGANIZATIONS 53

9 GLOBAL OSTEOSARCOMA MARKET, BY REGION
9.1 OVERVIEW 54

9.2 AMERICAS 56

9.2.1 NORTH AMERICA 60

9.2.2 LATIN AMERICA 69

9.3 EUROPE 73

9.3.1 WESTERN EUROPE 76

9.3.2 EASTERN EUROPE 99

9.4 ASIA-PACIFIC 103

9.4.1 JAPAN 107

9.4.2 CHINA 110

9.4.3 INDIA 113

9.4.4 SOUTH KOREA 116

9.4.5 REST OF ASIA-PACIFIC 119

9.5 MIDDLE EAST & AFRICA 123

9.5.1 MIDDLE EAST 127

9.5.2 AFRICA 130

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 134

10.2 KEY DEVELOPMENTS 134

11 COMPANY PROFILES
11.1 PFIZER INC. 136

11.1.1 COMPANY OVERVIEW 136

11.1.2 FINANCIAL OVERVIEW 137

11.1.3 PRODUCTS/SERVICES OFFERED 137

11.1.4 KEY DEVELOPMENTS 138

11.1.5 SWOT ANALYSIS 138

11.1.6 KEY STRATEGIES 138

11.2 BRISTOL-MYERS SQUIBB COMPANY 139

11.2.1 COMPANY OVERVIEW 139

11.2.2 FINANCIAL OVERVIEW 139

11.2.3 PRODUCTS/SERVICES OFFERED 140

11.2.4 KEY DEVELOPMENTS 140

11.2.5 SWOT ANALYSIS 140

11.2.6 EY STRATEGIES 141

11.3 ELI LILLY AND COMPANY 142

11.3.1 COMPANY OVERVIEW 142

11.3.2 FINANCIAL OVERVIEW 143

11.3.3 PRODUCTS/SERVICES OFFERED 143

11.3.4 KEY DEVELOPMENTS 143

11.3.5 SWOT ANALYSIS 144

11.3.6 KEY STRATEGIES 144

11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 145

11.4.1 COMPANY OVERVIEW 145

11.4.2 FINANCIAL OVERVIEW 146

11.4.3 PRODUCTS/SERVICES OFFERED 146

11.4.4 KEY DEVELOPMENTS 146

11.4.5 SWOT ANALYSIS 147

11.4.6 KEY STRATEGIES 147

11.5 BAXTER INTERNATIONAL 148

11.5.1 COMPANY OVERVIEW 148

11.5.2 FINANCIAL OVERVIEW 148

11.5.3 PRODUCTS/SERVICES OFFERED 149

11.5.4 KEY DEVELOPMENTS 149

11.5.5 SWOT ANALYSIS 150

11.5.6 KEY STRATEGIES 150

11.6 NOVARTIS AG 151

11.6.1 COMPANY OVERVIEW 151

11.6.2 FINANCIAL OVERVIEW 151

11.6.3 PRODUCTS/SERVICES OFFERED 152

11.6.4 KEY DEVELOPMENTS 152

11.6.5 SWOT ANALYSIS 153

11.6.6 KEY STRATEGIES 153

11.7 AUROBINDO PHARMA LIMITED 154

11.7.1 COMPANY OVERVIEW 154

11.7.2 FINANCIAL OVERVIEW 154

11.7.3 PRODUCTS/SERVICES OFFERED 155

11.7.4 KEY DEVELOPMENTS 155

11.7.5 SWOT ANALYSIS 156

11.7.6 KEY STRATEGIES 156

11.8 HIKMA PHARMACEUTICALS PLC 157

11.8.1 COMPANY OVERVIEW 157

11.8.2 FINANCIAL OVERVIEW 157

11.8.3 PRODUCTS/SERVICES OFFERED 158

11.8.4 KEY DEVELOPMENTS 158

11.8.5 SWOT ANALYSIS 159

11.8.6 KEY STRATEGIES 159

11.9 MYLAN NV 160

11.9.1 COMPANY OVERVIEW 160

11.9.2 FINANCIAL OVERVIEW 161

11.9.3 PRODUCTS/SERVICES OFFERED 162

11.9.4 KEY DEVELOPMENTS 162

11.9.5 SWOT ANALYSIS 163

11.9.6 KEY STRATEGIES 163

11.10 ADVAXIS, INC. 164

11.10.1 COMPANY OVERVIEW 164

11.10.2 FINANCIAL OVERVIEW 164

11.10.3 PRODUCTS/SERVICES OFFERED 164

11.10.4 KEY DEVELOPMENTS 165

11.10.5 SWOT ANALYSIS 165

11.10.6 KEY STRATEGIES 166

12 APPENDIX
12.1 REFERENCES 167

12.2 RELATED REPORTS 167





























 


List Of Tables


TABLE 1 PRIMARY INTERVIEWS 24

TABLE 2 LIST OF ASSUMPTIONS 28

TABLE 3 INCIDENCE OF OSTEOSARCOMA, BY AGE IN THE US 38

TABLE 4 CLINICAL TRIALS 39

TABLE 5 PIPELINE ANALYSIS 41

TABLE 6 GLOBAL OSTEOSARCOMA MARKET, BY TYPE 2016–2025 (USD MILLION) 42

TABLE 7 GLOBAL INTRAMEDULLARY OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 43

TABLE 8 GLOBAL JUXTACORTICAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 44

TABLE 9 GLOBAL EXTRASKELETAL OSTEOSARCOMA: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 44

TABLE 10 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 45

TABLE 11 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 46

TABLE 12 GLOBAL TREATMENT: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 46

TABLE 13 GLOBAL CHEMOTHERAPY: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 47

TABLE 14 GLOBAL SURGERY: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 47

TABLE 15 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 48

TABLE 16 GLOBAL DIAGNOSIS: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 48

TABLE 17 GLOBAL IMAGING: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 49

TABLE 18 GLOBAL BIOPSIES: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 49

TABLE 19 GLOBAL BLOOD TESTS: MARKET ESTIMATES & FORECAST, BY TYPE, 2016–2025 (USD MILLION) 50

TABLE 20 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 51

TABLE 21 GLOBAL HOSPITALS & CLINICS: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 52

TABLE 22 GLOBAL DIAGNOSTIC CENTERS: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 53

TABLE 23 GLOBAL ACADEMIC INSTITUTES & RESEARCH ORGANIZATIONS: MARKET ESTIMATES & FORECAST, BY REGION, 2016–2025 (USD MILLION) 53

TABLE 24 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2016–2025 (USD MILLION) 55

TABLE 25 AMERICAS: OSTEOSARCOMA MARKET, BY REGION, 2016–2025 (USD MILLION) 56

TABLE 26 AMERICAS: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 56

TABLE 27 AMERICAS: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 57

TABLE 28 AMERICAS: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 57

TABLE 29 AMERICAS: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 57

TABLE 30 AMERICAS: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 58

TABLE 31 AMERICAS: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 58

TABLE 32 AMERICAS: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 58

TABLE 33 AMERICAS: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 59

TABLE 34 AMERICAS: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 59

TABLE 35 AMERICAS: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 59

TABLE 36 NORTH AMERICA: OSTEOSARCOMA MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 60

TABLE 37 NORTH AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 60

TABLE 38 NORTH AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 60

TABLE 39 NORTH AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 61

TABLE 40 NORTH AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 61

TABLE 41 NORTH AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 61

TABLE 42 NORTH AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 62

TABLE 43 NORTH AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 62

TABLE 44 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 62

TABLE 45 NORTH AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 63

TABLE 46 NORTH AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 63

TABLE 47 US: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 63

TABLE 48 US: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 64

TABLE 49 US: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 64

TABLE 50 US: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 64

TABLE 51 US: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 64

TABLE 52 US: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 65

TABLE 53 US: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 65

TABLE 54 US: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 66

TABLE 55 US: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 66

TABLE 56 CANADA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 66

TABLE 57 CANADA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 67

TABLE 58 CANADA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 67

TABLE 59 CANADA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 67

TABLE 60 CANADA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 67

TABLE 61 CANADA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 68

TABLE 62 CANADA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 68

TABLE 63 CANADA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 68

TABLE 64 CANADA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 69

TABLE 65 CANADA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 69

TABLE 66 LATIN AMERICA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 69

TABLE 67 LATIN AMERICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 70

TABLE 68 LATIN AMERICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 70

TABLE 69 LATIN AMERICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 70

TABLE 70 LATIN AMERICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 70

TABLE 71 LATIN AMERICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 71

TABLE 72 LATIN AMERICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 71

TABLE 73 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 71

TABLE 74 LATIN AMERICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 72

TABLE 75 LATIN AMERICA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 72

TABLE 76 EUROPE: OSTEOSARCOMA MARKET, BY REGION, 2016–2025 (USD MILLION) 73

TABLE 77 EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 73

TABLE 78 EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 74

TABLE 79 EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 74

TABLE 80 EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 74

TABLE 81 EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 74

TABLE 82 EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 75

TABLE 83 EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 75

TABLE 84 EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 75

TABLE 85 EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 76

TABLE 86 EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 76

TABLE 87 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 76

TABLE 88 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 77

TABLE 89 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 77

TABLE 90 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 77

TABLE 91 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 78

TABLE 92 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 78

TABLE 93 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 78

TABLE 94 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 79

TABLE 95 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 79

TABLE 96 WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 79

TABLE 97 WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 80

TABLE 98 GERMANY: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 80

TABLE 99 GERMANY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 80

TABLE 100 GERMANY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 81

TABLE 101 GERMANY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 81

TABLE 102 GERMANY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 81

TABLE 103 GERMANY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 82

TABLE 104 GERMANY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 82

TABLE 105 GERMANY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 82

TABLE 106 GERMANY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 83

TABLE 107 GERMANY: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 83

TABLE 108 FRANCE: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 83

TABLE 109 FRANCE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 84

TABLE 110 FRANCE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 84

TABLE 111 FRANCE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 84

TABLE 112 FRANCE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 84

TABLE 113 FRANCE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 85

TABLE 114 FRANCE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 85

TABLE 115 FRANCE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 85

TABLE 116 FRANCE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 86

TABLE 117 FRANCE: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 86

TABLE 118 UK: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 86

TABLE 119 UK: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 87

TABLE 120 UK: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 87

TABLE 121 UK: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 87

TABLE 122 UK: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 87

TABLE 123 UK: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 88

TABLE 124 UK: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 88

TABLE 125 UK: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 88

TABLE 126 UK: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 89

TABLE 127 UK: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 89

TABLE 128 ITALY: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 89

TABLE 129 ITALY: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 90

TABLE 130 ITALY: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 90

TABLE 131 ITALY: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 90

TABLE 132 ITALY: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 90

TABLE 133 ITALY: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 91

TABLE 134 ITALY: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 91

TABLE 135 ITALY: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 91

TABLE 136 ITALY: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 92

TABLE 137 ITALY: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 92

TABLE 138 SPAIN: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 92

TABLE 139 SPAIN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 93

TABLE 140 SPAIN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 93

TABLE 141 SPAIN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 93

TABLE 142 SPAIN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 93

TABLE 143 SPAIN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 94

TABLE 144 SPAIN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 94

TABLE 145 SPAIN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 94

TABLE 146 SPAIN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 95

TABLE 147 SPAIN: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 95

TABLE 148 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 95

TABLE 149 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 96

TABLE 150 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 96

TABLE 151 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 96

TABLE 152 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 97

TABLE 153 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 97

TABLE 154 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 97

TABLE 155 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 98

TABLE 156 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 98

TABLE 157 REST OF WESTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 98

TABLE 158 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 99

TABLE 159 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 99

TABLE 160 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 99

TABLE 161 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 100

TABLE 162 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 100

TABLE 163 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 100

TABLE 164 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 101

TABLE 165 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 101

TABLE 166 EASTERN EUROPE: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 101

TABLE 167 EASTERN EUROPE: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 102

TABLE 168 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 103

TABLE 169 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 104

TABLE 170 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 104

TABLE 171 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 104

TABLE 172 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 105

TABLE 173 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 105

TABLE 174 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 105

TABLE 175 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 106

TABLE 176 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 106

TABLE 177 ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 106

TABLE 178 ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 107

TABLE 179 JAPAN: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 107

TABLE 180 JAPAN: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 107

TABLE 181 JAPAN: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 108

TABLE 182 JAPAN: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 108

TABLE 183 JAPAN: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 108

TABLE 184 JAPAN: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 109

TABLE 185 JAPAN: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 109

TABLE 186 JAPAN: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 109

TABLE 187 JAPAN: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 110

TABLE 188 JAPAN: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 110

TABLE 189 CHINA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 110

TABLE 190 CHINA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 111

TABLE 191 CHINA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 111

TABLE 192 CHINA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 111

TABLE 193 CHINA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 111

TABLE 194 CHINA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 112

TABLE 195 CHINA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 112

TABLE 196 CHINA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 112

TABLE 197 CHINA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 113

TABLE 198 CHINA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 113

TABLE 199 INDIA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 113

TABLE 200 INDIA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 114

TABLE 201 INDIA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 114

TABLE 202 INDIA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 114

TABLE 203 INDIA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 114

TABLE 204 INDIA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 115

TABLE 205 INDIA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 115

TABLE 206 INDIA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 115

TABLE 207 INDIA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 116

TABLE 208 INDIA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 116

TABLE 209 SOUTH KOREA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 116

TABLE 210 SOUTH KOREA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 117

TABLE 211 SOUTH KOREA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 117

TABLE 212 SOUTH KOREA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 117

TABLE 213 SOUTH KOREA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 117

TABLE 214 SOUTH KOREA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 118

TABLE 215 SOUTH KOREA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 118

TABLE 216 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 118

TABLE 217 SOUTH KOREA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 119

TABLE 218 SOUTH KOREA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 119

TABLE 219 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 119

TABLE 220 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 120

TABLE 221 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 120

TABLE 222 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 120

TABLE 223 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 121

TABLE 224 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 121

TABLE 225 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 121

TABLE 226 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 122

TABLE 227 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 122

TABLE 228 REST OF ASIA-PACIFIC: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 122

TABLE 229 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY REGION, 2016–2025 (USD MILLION) 123

TABLE 230 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 123

TABLE 231 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 124

TABLE 232 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 124

TABLE 233 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 124

TABLE 234 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 125

TABLE 235 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 125

TABLE 236 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 125

TABLE 237 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 126

TABLE 238 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 126

TABLE 239 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 126

TABLE 240 MIDDLE EAST: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 127

TABLE 241 MIDDLE EAST: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 127

TABLE 242 MIDDLE EAST: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 127

TABLE 243 MIDDLE EAST: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 128

TABLE 244 MIDDLE EAST: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 128

TABLE 245 MIDDLE EAST: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 128

TABLE 246 MIDDLE EAST: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 129

TABLE 247 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 129

TABLE 248 MIDDLE EAST: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 129

TABLE 249 MIDDLE EAST: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 130

TABLE 250 AFRICA: OSTEOSARCOMA MARKET, BY TYPE, 2016–2025 (USD MILLION) 130

TABLE 251 AFRICA: OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT 2016–2025 (USD MILLION) 130

TABLE 252 AFRICA: OSTEOSARCOMA MARKET FOR TREATMENT, BY TYPE, 2016–2025 (USD MILLION) 131

TABLE 253 AFRICA: OSTEOSARCOMA MARKET FOR CHEMOTHERAPY, BY TYPE, 2016–2025 (USD MILLION) 131

TABLE 254 AFRICA: OSTEOSARCOMA MARKET FOR SURGERY, BY TYPE, 2016–2025 (USD MILLION) 131

TABLE 255 AFRICA: OSTEOSARCOMA MARKET FOR DIAGNOSIS, BY TYPE 2016–2025 (USD MILLION) 132

TABLE 256 AFRICA: OSTEOSARCOMA MARKET FOR IMAGING, BY TYPE 2016–2025 (USD MILLION) 132

TABLE 257 AFRICA: OSTEOSARCOMA MARKET FOR BIOPSIES, BY TYPE 2016–2025 (USD MILLION) 132

TABLE 258 AFRICA: OSTEOSARCOMA MARKET FOR BLOOD TESTS, BY TYPE 2016–2025 (USD MILLION) 133

TABLE 259 AFRICA: OSTEOSARCOMA MARKET, BY END USER, 2016–2025 (USD MILLION) 133

TABLE 260 MAJOR MANUFACTURERS IN THE GLOBAL OSTEOSARCOMA MARKET 134

TABLE 261 KEY DEVELOPMENTS BY PLAYERS IN THE MARKET 135

TABLE 262 PFIZER INC.: PRODUCTS/SERVICES OFFERED 137

TABLE 263 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 140

TABLE 264 ELI LILLY AND COMPANY: PRODUCTS OFFERED 143

TABLE 265 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED 146

TABLE 266 BAXTER INTERNATIONAL: PRODUCTS/SERVICES OFFERED 149

TABLE 267 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 152

TABLE 268 AUROBINDO PHARMA LIMITED: PRODUCTS/SERVICES OFFERED 155

TABLE 269 AUROBINDO PHARMA LIMITED: KEY DEVELOPMENTS 155

TABLE 270 HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED 158

TABLE 271 HIKMA PHARMACEUTICALS PLC: KEY DEVELOPMENTS 158

TABLE 272 MYLAN NV: PRODUCTS/SERVICES OFFERED 162

TABLE 273 ADVAXIS, INC.: PRODUCTS/SERVICES OFFERED 164

TABLE 274 ADVAXIS, INC.: KEY DEVELOPMENTS 165
 


List Of Figures


FIGURE 1 MARKET SYNOPSIS 18

FIGURE 2 GLOBAL OSTEOSARCOMA MARKET: STRUCTURE 21

FIGURE 3 RESEARCH PROCESS 23

FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACHES 26

FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET 29

FIGURE 6 DRIVERS: IMPACT ANALYSIS 31

FIGURE 7 RESTRAINTS: IMPACT ANALYSIS 32

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL OSTEOSARCOMA MARKET 34

FIGURE 9 VALUE CHAIN ANALYSIS OF THE GLOBAL OSTEOSARCOMA MARKET 36

FIGURE 10 PIPELINE ANALYSIS 41

FIGURE 11 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2018 (% SHARE) 42

FIGURE 12 GLOBAL OSTEOSARCOMA MARKET, BY TYPE, 2018 TO 2025 (USD MILLION) 43

FIGURE 13 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018 (% SHARE) 45

FIGURE 14 GLOBAL OSTEOSARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018 TO 2025 (USD MILLION) 46

FIGURE 15 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2018 (% SHARE) 51

FIGURE 16 GLOBAL OSTEOSARCOMA MARKET, BY END USER, 2018 TO 2025 (USD MILLION) 52

FIGURE 17 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2018 AND 2025 (USD MILLION) 54

FIGURE 18 GLOBAL OSTEOSARCOMA MARKET, BY REGION, 2018 (% SHARE) 54

FIGURE 19 AMERICAS: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE) 56

FIGURE 20 EUROPE: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE) 73

FIGURE 21 ASIA-PACIFIC: OSTEOSARCOMA MARKET SHARE, BY COUNTRY, 2018 (% SHARE) 103

FIGURE 22 MIDDLE EAST & AFRICA: OSTEOSARCOMA MARKET SHARE, BY REGION, 2018 (% SHARE) 123

FIGURE 23 PFIZER INC. FINANCIAL OVERVIEW SNAPSHOT 137

FIGURE 24 PFIZER INC.: SWOT ANALYSIS 138

FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 139

FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 140

FIGURE 27 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 143

FIGURE 28 ELI LILLY AND COMPANY: SWOT ANALYSIS 144

FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 146

FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 147

FIGURE 31 BAXTER INTERNATIONAL: FINANCIAL OVERVIEW SNAPSHOT 148

FIGURE 32 BAXTER INTERNATIONAL: SWOT ANALYSIS 150

FIGURE 33 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 151

FIGURE 34 NOVARTIS AG: SWOT ANALYSIS 153

FIGURE 35 AUROBINDO PHARMA LIMITED: FINANCIAL OVERVIEW SNAPSHOT 154

FIGURE 36 AUROBINDO PHARMA LIMITED: SWOT ANALYSIS 156

FIGURE 37 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT 157

FIGURE 38 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS 159



FIGURE 39 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT 161

FIGURE 40 MYLAN NV: SWOT ANALYSIS 163

FIGURE 41 ADVAXIS, INC.: FINANCIAL OVERVIEW SNAPSHOT 164

FIGURE 42 ADVAXIS, INC.: SWOT ANALYSIS 165
 


Water Purifiers: Global Markets

Report Scope:The water purifiers market is segmented into the following categories - - By Technology: Gravity Purifiers, RO Purifiers, UV Purifiers, Sediment Filters, Water Softeners and Hybrid Purifiers.- By Sales

USD 5500 View Report

Patient Safety and Risk Management Software: Global Markets

Report Scope:The patient safety and risk management software market is segmented into the following categories - By type:- Risk management and safety solutions.- Claims management solutions.- Governance, risk and compliance

USD 5500 View Report

Europe Osteosarcoma Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Osteosarcoma market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by the end

USD 3000 View Report

Global Osteosarcoma Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Osteosarcoma is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available